Back to Journals » Therapeutics and Clinical Risk Management » Volume 3 » Issue 5

The use of dorzolamide versus other hypotensive agents to prevent glaucomatous progression

Authors Savvas Diafas, Douglas G Day, Jeanette A Stewart, William C Stewart

Published 15 November 2007 Volume 2007:3(5) Pages 725—732

Savvas Diafas1, Douglas G Day2, Jeanette A Stewart3, William C Stewart3,4

1Papageorgiou General Hospital, Thessaloniki, Greece; 2Omni Eye Services, Atlanta, GA, USA; 3PRN Pharmaceutical Research Network, LLC, Charleston, SC, USA; 4Carolina Eye Institute, University of South Carolina, School of Medicine, Columbia, SC, USA

Purpose: To evaluate progression rates with dorzolamide compared with other hypotensive agents in primary open-angle glaucoma.

Methods: Patients who were treated over 5 years with dorzolamide versus other hypotensive agents were reviewed. The groups were matched by intraocular pressure, cardiovascular history, and age.

Results: In 50 matched pairs, 2 (4%) of dorzolamide and 7 (14%) of control patients suffered glaucomatous progression (p = 0.09). Progressed dorzolamide patients had pressures of 13 versus 15–20 mmHg in the control group. Control patients progressed after 26.4 months and dorzolamide patients after 38.9 months.

Conclusions: Although the results were not statistically significant, this pilot trial demonstrated a trend towards less glaucomatous progression in patients treated with an assumed active blood flow product. In addition, progression was delayed and occurred at lower pressures in the active blood flow group. This pilot trial suggests that future prospective, long-term, clinical outcomes studies in patients treated with a medicine with a positive ocular blood flow effect may be warranted.

Keywords: blood flow, ocular hypotensive agents, dorzolamide, glaucomatous progression

Download Article [PDF] 

Readers of this article also read:

The "Pulse Time Index of Norm" highly correlates with the left ventricular mass index in patients with arterial hypertension

Posokhov IN, Kulikova NN, Starchenkova IV, Grigoricheva EA, Evdokimov VV, Orlov AV, Rogoza AN

Vascular Health and Risk Management 2014, 10:139-144

Published Date: 19 March 2014

Epiretinal membrane surgery for combined hamartoma of the retina and retinal pigment epithelium: role of multimodal analysis

Bruè C, Saitta A, Nicolai M, Mariotti C, Giovannini A

Clinical Ophthalmology 2013, 7:179-184

Published Date: 20 January 2013

Corrigendum

Siebeling L, Puhan MA, Muggensturm P, Zoller M, ter Riet G

Clinical Epidemiology 2012, 4:257-258

Published Date: 5 October 2012

Erratum

Marusza W, Mlynarczyk G, Olszanski R, Netsvyetayeva I, Obrowski M, Iannitti T, Palmieri B

International Journal of Nanomedicine 2012, 7:4119-4120

Published Date: 27 July 2012

Effect of molecular weight of polyethyleneimine on loading of CpG oligodeoxynucleotides onto flake-shell silica nanoparticles for enhanced TLR9-mediated induction of interferon-α

Manoharan Y, Ji Q, Yamazaki T, Chinnathambi S, Chen S, Ganesan S, Hill JP, Ariga K, Hanagata N

International Journal of Nanomedicine 2012, 7:3625-3635

Published Date: 16 July 2012

Editor's choice

Sørensen HT

Clinical Epidemiology 2012, 4:157-158

Published Date: 9 July 2012

Prevention of atherosclerosis in patients living with HIV

Ferruccio De Lorenzo, Marta Boffito, Sophie Collot-Teixeira, Brian Gazzard, John L McGregor, Kevin Shotliff, Han Xiao

Vascular Health and Risk Management 2009, 5:287-300

Published Date: 26 March 2009